INTRODUCTION
Soft-tissue disorders are the third most common rheumatologic condition in the UK, with a reported prevalence of 18 cases per 1,000 people. 1 These disorders, which primarily affect tendon, are the main reasons for a musculoskeletal consultation with a general practitioner, and comprised 30% of all such consultations in a 1-year study. 2 This is probably an under estimate of the scale of the problem, because only 40% of elderly individuals (over 70 years of age) with shoulder pain seek treatment. 3 Although many soft-tissue problems are treated by a general practitioner, often with NSAIDs, cortico steroid injection or physiotherapy, a substantial proportion of new patient consultations with rheumatologists Chronic tendon pathology (tendinopathy), although common, is difficult to treat. Tendons possess a highly organized fibrillar matrix, consisting of type I collagen and various 'minor' collagens, proteoglycans and glycoproteins. The tendon matrix is maintained by the resident tenocytes, and there is evidence of a continuous process of matrix remodeling, although the rate of turnover varies at different sites. A change in remodeling activity is associated with the onset of tendinopathy. Major molecular changes include increased expression of type III collagen, fibronectin, tenascin C, aggrecan and biglycan. These changes are consistent with repair, but they might also be an adaptive response to changes in mechanical loading. Repeated minor strain is thought to be the major precipitating factor in tendinopathy, although further work is required to determine whether it is mechanical overstimulation or understimulation that leads to the change in tenocyte activity. Metalloproteinase enzymes have an important role in the tendon matrix, being responsible for the degradation of collagen and proteoglycan in both healthy patients and those with disease. Metalloproteinases that show increased expression in painful tendinopathy include ADAM (a disintegrin and metalloproteinase)-12 and MMP (matrix metalloproteinase)-23. The role of these enzymes in tendon pathology is unknown, and further work is required to identify novel and specific molecular targets for therapy.
are for soft-tissue rheumatism. Secondary referral rates vary widely, but one study reported that 17% of new patients seen in a rheumatology clinic had soft-tissue complaints. 4 Conditions affecting tendons, which include chronic pain and rupture, are now generally referred to as 'tendinopathies' in preference to terms such as 'tendinosis' and 'tendinitis', because this terminology makes no assumptions about the underlying pathology. Although the role of inflammation is still debated, it has long been known that tendino pathies are primarily degenerative conditions-there is usually an absence of inflammatory cells in or around the lesion. 5 Consequently, it should be no surprise that treatment with anti-inflammatory drugs showed little benefit in controlled trials. 6 In fact, there is remarkably little evidence that any conventional therapies are effective. 7 It has taken several years for research interest to grow, but the molecular mechanisms underlying the cause and progression of tendinopathy are beginning to be elucidated. This article will review the molecular pathology of tendon, and discuss how this knowledge might provide potential new targets for the treatment of chronic tendino pathies.
MOLECULAR COMPOSITION OF TENDON
The main principles of tendon structure and composition are shown schematically in Figure 1 , and have been reviewed elsewhere. 8, 9 Key elements of the extracellular matrix are the dense, fibrillar network of predominantly parallelaligned collagen fibers, principally consisting of type I collagen but also containing lesser amounts of various 'minor' collagens, several proteoglycans and a growing list of glyco proteins. 8 Although the role and function of many of these components are still poorly defined, the molecular architecture of the matrix is ideally suited primarily for the transmission of tensile load; however, tendons also function to stabilize joints and absorb large shocks, protecting muscles from damage.
There are variations in structure and composition within a tendon, particularly at the myotendinous junction and bone insertion sites (enthesis) but also at sites where the tendon is compressed, passes through soft-tissue pulleys, abuts against ligaments or traverses bony prominences. 9 Fibrocartilaginous regions are formed in tendons in response to compressive load or shear, an adaptive response that protects the tendon from damage. The molecular architecture of tendon fibrocartilage has been extensively studied, demonstrating increased expression of molecules normally asso ciated with articular cartilage, including type II collagen and aggrecan. 9
CELL POPULATIONS OF TENDON
The fibroblast-like cells that populate tendon are known as 'tenocytes' , which are thought to be distinct from other connective tissue cells, although there are currently no specific molecular markers that can be used to character ize them. 10 There are a variety of cell phenotypes described in histologic studies of tendon, with more rounded 'fibrochondrocyte' cells in fibrocartilaginous regions, often arranged in columns at the insertion, compared with elongated and dispersed fibroblasts within fibers in the tensile-load-bearing regions of the tendon mids ubstance. 11 There are synovial-like cells in the endotenon and epitenon, the thin layers of loose connective tissue that surround the fiber bundles or fascicles. 12 The different cell populations have distinct activities in matrix synthesis, and are responsive to cytoskeleton-mediated matrix interactions and changes in their mechanical environment. 12-14 Additional cells include smooth muscle and endothelial cells associated with blood vessels, which can be found passing through the endotenon and epitenon. Fine nerve processes and nerve endings are sparse but also present, usually in proximity to the blood vessels, which are more abundant in the epitenon and enveloping paratenon. 15 After tendon injury, most repair activity is associated with cells from the epitenon and endotenon, which migrate to the lesion and synthesize new matrix. 16 A proportion of these cells is thought to be derived from a resident population of stem cells, which can differentiate into a variety of mesenchymal tissues, such as bone, fat and cartilage, in addition to tendon. 10
TENDON MATRIX ADAPTATION AND REMODELING
In addition to internal variations within tendon, there are variations in structure, composition and cell phenotype between tendons from different sites, and, increasingly, it is recognized that tendons are 'engineered' according to the functional demands on them in specific anatomic locations. 17 There are variations in the content of proteoglycan and collagen, and there is evidence of different rates of matrix turnover. Highly stressed tendons, such as the supraspinatus in the rotator cuff, show increased levels of collagen remodeling compared with those that are not under high stress, for example the distal biceps tendon in the forearm, which has much lower rates of collagen turnover. 18, 19 The continual process of matrix remodeling is a constitutive (albeit slow) activity in normal tendons, affecting proteoglycans in addition to collagen, 20, 21 and is thought to be primarily mediated by metalloproteinases acting in the extracellular environment, such as matrix metalloproteinases (MMPs) and a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS).
MMPs and ADAMTS have been reviewed elsewhere. 22, 23 Briefly, there are 23 MMPs in humans, which have a wide range of matrix substrates. Several of these enzymes (MMP1, MMP2, MMP8, MMP13 and MMP14) have activity against fibrillar collagen. Because few enzymes can cleave fibrillar collagen at neutral pH, regulation of this activity is thought to be a key step in the remodeling process in both health and disease. Proteoglycans are primarily degraded by enzymes of the ADAMTS family known as 'aggrecanases', which include ADAMTS1, ADAMTS4, ADAMTS5, ADAMTS8 and ADAMTS9, although precisely which enzyme is involved in the turnover of tendon proteoglycan is currently unknown. The activity of metalloproteinases is highly regulated at multiple levels, including transcription, activation and inhibition by tissue inhibitors of metallo proteinase (TIMPs). 22 Analysis of metalloproteinase gene expression in human Achilles tendon showed that almost all of the 23 MMP and 19 ADAMTS family members were detectable in normal tendon, although levels of expression varied widely. 24 These enzymes are important in regulating cell activity as well as matrix degradation, and they have roles in growth, development and repair, and also pathologic processes, including inflamma tion and degeneration. 25 Evidence of their importance in tendon health is provided by the observation that broad-spectrum metalloproteinase inhibitors used in clinical trials caused a musculoskeletal syndrome similar to tendinopathy that resolved after treatment ended. 26 Fluoroquinolone antibiotics, such as ciprofloxacin, can also induce tendinopathy in some patients, and these drugs can modulate MMP expression by tenocytes, at least in vitro. 27 Doxycycline, which inhibits several MMPs, significantly reduced the mechanical properties of healing tendons, demonstrating the importance of MMPs in tendon repair. 28
MACROSCOPIC AND MICROSCOPIC OBSERVATIONS OF TENDINOPATHY
Tendons commonly affected by tendinopathy include the supraspinatus and long head of biceps in the shoulder, medial and lateral extensors of the elbow, the patellar, the Achilles tendon and the posterior tibialis. In most cases, with the notable exception of the Achilles tendon, the site affected is at or near the insertion in a fibrocartilaginous region of the tendon. 29 There are several common features of these sites: they are more highly stressed than other tendons, often exposed to repeated strains, including shear or compressive forces, and relatively less vascularized than the tendon midsubstance.
Histopathology of painful tendons shows changes in cellularity (both increased and decreased), cell rounding, decreased matrix organization and increased infiltration of blood vessels. 30 The abnormal vascularity has been associated with tendon pain. 31 Ruptured tendons show similar degenerative features, although there is generally reduced cellularity and little evidence of neovascularization. 32 The
MOLECULAR PATHOLOGY OF TENDINOPATHY
Biochemical and molecular studies of chronic tendinopathy during the past 15 years have increased our understanding of the underlying pathology; the main findings are summarized in Figure 2 . In pathologic human tendon, there is increased expression of the messenger RNA of collagen types I and III, and increased amounts of type III collagen protein are found in the tendon matrix. 33 The levels of fibronectin and tenascin C are also increased, consistent with a healing response. 33 There is an increased level of glycosaminoglycan in the matrix 33 and increased expression of the chondroitin sulfate proteoglycans, aggrecan and biglycan, even in the midsubstance of the Achilles tendon (in which fibrocartilage is not normally found), consistent with an adaptive response to shear or compression. 34 Versican messenger RNA levels were unchanged in painful tendons, although there were changes in splicing of the gene that would affect the quantity of glycosaminoglycan attached to the mature protein. 35 There are changes in the expression and activity of various metalloproteinases, and changes in the level of TIMPs that are consistent with increased proteolytic activity in degenerate tendons. 33 Pathologic (torn) rotator cuff tendons showed greatly increased collagen ase (MMP1) activity and reduced gelatinase (MMP2) and stromelysin (MMP3) activity compared with normal tendons; these changes correlated with levels of collagen turnover in the tissues. 19 A study of gene expression in Achilles tendons showed that painful and ruptured tendons had distinct patterns of expression, consistent with quantitative and qualitative differences in catabolic activity in the different clinical entities. 24 Ruptured tendons showed increased levels of expression of MMP1, MMP9, MMP19, MMP25 and TIMP1 and decreased levels of expression of MMP3, MMP7, TIMP2, TIMP3 and TIMP4. Painful tendons showed reduced expression of MMP3, MMP10 and TIMP3 and increased expression of ADAM12 and MMP23. Little is known about the role and function of ADAM12 and MMP23 in tendon, although both have been associated with changes in cell phenotype: ADAM12 with myo genesis and lipidogenesis, and MMP23 with endo chondral ossification. 36, 37 In summary, the changes in the composition of tendon matrix are consistent with changes in cell-mediated matrix remodeling that precede the onset of clinical symptoms, and these changes are mediated, at least in part, by metalloproteinase enzymes.
The cellular and molecular processes that drive the changes in the remodeling of tendon matrix in tendinopathy are yet to be determined. It is uncertain to what extent the remodeling represents a limited repair response to microscopic fiber damage or an adaptive response to changes in cell-loading patterns. Excessive microstrain or 'overuse' acting on the tenocytes has been shown to elicit the expression of several inflammatory mediators and MMPs, at least in vitro, and it is suggested that this might trigger increased proteolytic activity in the tendon; 38 however, the levels of strain required to elicit this response are high, potentially much higher than the strains experienced by cells in vivo.
More recently, it has been shown that rat tenocytes cultured in three-dimensional collagen gels will upregulate their expression of MMP13, the major rodent collagenase, if the gels become free floating and contract. 39 These studies were extended to a study of stretched tendons in vitro, and it was shown that upregulation of MMP13 occurred after failure of one or more of the fiber bundles. 40 Thus, it seems that MMP output is attenuated by strain on the tendon cells through the cytoskeleton, and damage to tendon fibers results in the release of the cells from this strain regulation, resulting in increased collagenase activity and matrix degradation. Although there is an absence of inflammatory cells in or around the lesion, this does not mean that inflammatory mediators are not implicated in tendinopathy, at least at some stage in the disease. Although levels of prostaglandin E 2 were not significantly higher in the fluids surrounding painful tendons, 41,42 levels of prostaglandin E 2 and several other inflammatory mediators, such as thromboxane, bradykinin and interleukin (IL)-6, are increased in peritendinous tissue after prolonged exercise. [43] [44] [45] Other studies have reported increased levels of IL-1 in the tissues surrounding painful tendons, such as the bursa in the shoulder. 46 Increased expression Platelet-rich plasma injection Contains growth factors (e.g. transforming growth factor β and platelet-derived growth factor) that promote matrix synthesis and tissue repair a Few treatments for chronic tendinopathy are targeted against specific molecular processes. In most cases, there is little or no evidence of therapeutic effectiveness, especially in the long term. Large, appropriately controlled clinical trials with extended follow-up are required.
of cyclo-oxygenase 2 was associated with patellar tendinopathy, 47 and repeated injection of prostaglandin around the tendon has been shown to induce a degenera tive tendinopathy in animal models. 48 The expression of growth factors and other potential modulators of tendon cell activity has been shown to increase in tendino pathy, including transforming growth factor β, platelet-derived growth factor receptor and neuro transmitters, such as glutamate and substance P. 42, 47, [49] [50] [51] These changes might, however, be part of the healing response of the tissue and a requisite for tendon repair. 52, 53 
NEW TREATMENTS FOR TENDINOPATHY AND FUTURE RESEARCH DIRECTIONS
A summary of current treatments and new therapies in development is shown in Table 1 . Exercise is important in both prevention and treatment of tendinopathy. Eccentric exercise therapy has been reported to have some effect in prospective, randomized trials in athletic patients; 54, 55 however, a review of 20 published trials found that there was little evidence of a positive effect on clinical outcomes, such as reduction of pain, return to function and patient satisfaction. 56 Shock-wave therapy, which is thought to function on the tenocytes to stimulate repair, might be effective in a carefully selected group of patients, 57 although other studies have reported no significant effect. 58, 59 Growth factors have been used for several years in an attempt to improve tendon healing, but there is currently no evidence that these are effective in tendinopathies. Nitric oxide, applied using topical nitroglycerin patches, has been shown to improve outcomes in randomized, double-blind, placebo-controlled trials, possibly by enhancing collagen synthesis. [60] [61] [62] Sclerosant injections have been shown to give at least shortterm benefit, 63 and might provide a rational basis for targeting neovascularization in painful tendinopathy, which might be triggered initially by hypoxia and regulated by levels of endostatin and vascular endothelial growth factor. 64, 65 Aging might reduce the ability of tenocytes to remodel and repair lesions, supporting the use of stem-cell therapies that involve the injection of bone-marrow-derived cells into injured or degenerate tendon; this approach is currently being used to treat equine tendinopathy. 66 Gene therapy to introduce specific anabolic or anticatabolic factors shows promise, and preparatory studies have demonstrated the feasibility of this approach in animal tendons. 67 Tissue engineering constructs are also being developed to repair or replace damaged tendons, although much more work is required before these constructs are used in humans. 68 
CONCLUSIONS
Future work is required to fully define the etiology of tendinopathy, including the development and validation of both in vitro and in vivo models. In vitro models will enable the investigation of the regulation of tenocyte activity by factors such as mechanical strain, cell-matrix interactions, cytokines, soluble factors, enzymes and signaling molecules. There are now several promising animal models, 69, 70 and further work using genome-wide screening and specific gene knockouts or transgenic animals should yield exciting new insights into the cause and progression of the disease. Metalloproteinases might be important in tendon pathology, but there are other classes of protease (e.g. cysteine, aspartate and serine proteases) that have, so far, received little attention. Because some enzyme activities are required in healthy and repairing tendon, it is essential to differentiate 'good' enzymes from those that are 'bad' , so that drugs targeting specific activities can be developed for the treatment of tendinopathy.
KEY POINTS
■ Tendon disorders are common, often underreported and a major clinical problem ■ Most current treatments for tendinopathy are neither effective nor evidence-based ■ Molecular processes underlying tendinopathy are now being elucidated: metalloproteinase enzymes are thought to have a key role in the regulation of the activity of tendon cells and matrix remodeling in both normal and pathologic tendon ■ The potential roles of neuropeptides, inflammatory mediators and mechanical strain (either too much or too little) acting on the resident tenocytes are the source of some controversy and require in-depth investigation using in vitro and in vivo models ■ Excessive or inappropriate activity of destructive matrix-degrading enzymes might be a novel therapeutic target for tendinopathy; other treatments in development include the injection of stem cells, gene therapy and tissue engineering to repair or replace damaged tendon tissue
